Design Therapeutics (DSGN) Cash from Operations (2020 - 2026)

Design Therapeutics has disclosed Cash from Operations across 7 years of filings, most recently posting 16431000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 16431000.0, up 2.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 54000000.0 (down 13.79% YoY), and the FY2025 annual result was 54358000.0, down 26.11% from the prior year.
• Cash from Operations came in at 16431000.0 for Q1 2026 at Design Therapeutics, down from 11966000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 9546000.0 in Q3 2024 to a low of 17424000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 12798000.0 (2023), against an average of 13163000.0.
• Across the five-year window, Cash from Operations tumbled 219.91% in 2022 and soared 34.32% in 2024, its largest moves.
• Design Therapeutics' Cash from Operations stood at 15091000.0 in 2022, then grew by 15.19% to 12798000.0 in 2023, then advanced by 22.96% to 9860000.0 in 2024, then fell by 21.36% to 11966000.0 in 2025, then slumped by 37.31% to 16431000.0 in 2026.
• The last three Cash from Operations figures came in at 16431000.0 (Q1 2026), 11966000.0 (Q4 2025), and 11162000.0 (Q3 2025), per Business Quant data.